Aigen Investment Management’s Pacira BioSciences PCRX Stock Holding History

Aigen Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,647	Closed	-$224K	–	927
2023 Q4	$224K	Sell	6,647 -4,044	-38%	-$118K	0.04%	620
2023 Q3	$328K	Buy	+10,691	New	+$385K	0.06%	492
2020 Q4	–	Sell	-46,582	Closed	-$2.8M	–	976
2020 Q3	$2.8M	Buy	46,582 +15,939	+52%	+$926K	0.36%	63
2020 Q2	$1.61M	Sell	30,643 -9,243	-23%	-$386K	0.21%	135
2020 Q1	$1.34M	Buy	39,886 +39,832	+73,763%	+$1.65M	0.18%	154
2019 Q4	$2K	Buy	+54	New	+$2.29K	﹤0.01%	1051

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Aigen Investment Management's PCRX Position: Q1 2024 in Review

Aigen Investment Management sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 6,647 shares — an estimated $224K sold.

Aigen Investment Management first reported a position in PCRX in Q4 2019 and held it in 6 quarters. The position peaked at $2.8M in Q3 2020. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

Aigen Investment Management reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
Aigen Investment Management sold 6,647 Pacira BioSciences shares in Q1 2024, an estimated $224K.
Aigen Investment Management first reported a position in Pacira BioSciences in Q4 2019 and held it in 6 quarters.
Aigen Investment Management's Pacira BioSciences position peaked at $2.8M in Q3 2020.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Aigen Investment Management's 13F filing for Q1 2024, filed 14 May 2024.